clinical trial · NCT05701800
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ModernaTX, Inc.·phase1·terminated·n = 659
Herpes ZostermRNA-1468PlaceboShingrix
brief summary
The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
started
Jan 23, 2023
primary completion
Dec 31, 2025
completion
Dec 31, 2025
last updated
Aug 5, 2026
official title
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol